Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Moleculin Shares Jump on Progress With Virus-Drug Candidate
01:36pm, Tuesday, 21'st Jul 2020
Moleculin Biotech says independent testing confirms the antiviral activity of its coronavirus treatment candidate.
Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment
12:30pm, Tuesday, 21'st Jul 2020
Shares of small-cap Moleculin Biotech Inc. undefined soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing...
Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment
11:46am, Tuesday, 21'st Jul 2020
Shares of small-cap Moleculin Biotech Inc. soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing confirmed antiviral activity for WP1122, its candidate as
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
11:30am, Tuesday, 21'st Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Moleculin Biotech (NASDAQ:MBRX) Shares Gap Down to $1.07
01:54am, Sunday, 19'th Jul 2020
Moleculin Biotech Inc (NASDAQ:MBRX) shares gapped down before the market opened on Friday . The stock had previously closed at $1.11, but opened at $1.07. Moleculin Biotech shares last traded at $1.03
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group - Markets
05:06pm, Thursday, 16'th Jul 2020
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Moleculin Biotech (MBRX – Research
Moleculin Surges on Manufacturing Deal for Coronavirus Therapy
03:11pm, Thursday, 16'th Jul 2020
Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.
Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
11:30am, Wednesday, 15'th Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?
03:30pm, Friday, 03'rd Jul 2020
Is (MBRX) Outperforming Other Medical Stocks This Year?
Oppenheimer Sticks to Its Buy Rating for Moleculin Biotech (MBRX) - Markets
04:54pm, Thursday, 02'nd Jul 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Moleculin Biotech (MBRX – Research Report),
Moleculin Provides Update on Annamycin Clinical Development
11:30am, Thursday, 02'nd Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know
09:50pm, Wednesday, 01'st Jul 2020
In the latest trading session, Moleculin Biotech, Inc. (MBRX) closed at $0.96, marking a -0.38% move from the previous day.
New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model
11:30am, Wednesday, 01'st Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Moleculin Biotech, Inc. (NASDAQ:
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
12:35pm, Monday, 29'th Jun 2020
NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.
